Pfizer lifts profit forecast on strong sales of cancer, heart drugs
Adds price negotiation details, paragraphs 8-10, RSV in paragraphs 19-20, graphic on drug sales
By Bhanvi Satija and Michael Erman
July 30 (Reuters) -Pfizer PFE.N raised its annual profit forecast on Tuesday, helped by cancer treatments acquired through a $43 billion deal for Seagen and strong sales of its heart disease drug as the company deals with a sharp revenue drop from COVID products.
The market for Pfizer's COVID-19 vaccine and treatment has shrunk by billions of dollars a year.
Pfizer CEO Albert Bourla responded with several acquisitions, including the Seagen deal and cost-cutting measures. The New York-based drugmaker has also sharpened its focus on cancer treatments.
Investors fled from Pfizer as COVID worries declined and the company's shares are trading at around half their pandemic-era highs.
J.P. Morgan analyst Chris Schott said he expects Pfizer's stock to continue to trade in the current range due to limited revenue growth and stronger expectations for many of its rivals.
"We believe stronger new launch performance and/or further progress on the pipeline will be necessary to significantly change the narrative," he wrote in a research note.
Pfizer shares were off less than 1% at $30.44.
Sales of Eliquis, the blood thinner it shares with Bristol Myers Squibb BMY.N, are expected to be curtailed starting in 2026, when the U.S. begins using negotiated prices for some drugs for its Medicare health plan for people age 65 and over.
Pfizer executives echoed comments from other drugmakers earlier this month, saying it expects to be able to navigate the impact on Eliquis, which it sees as an important drug for the company for the foreseeable future.
Overall, the impact of the law allowing U.S. price negotiations on Pfizer "is somewhat muted as you think about it economically," Chief Financial Officer David Denton said. He said many products that could be selected for negotiation in the coming years will be nearing the end of their patent protection.
Quarterly sales grew 3% operationally to $13.3 billion, marking its first quarter of sales growth since COVID revenue peaked in late 2022.
The quarter was helped by sales of its heart disease drug, sold under brand names Vyndaqel or Vyndamax and cancer therapy Padcev.
Pfizer now expects annual profit to be in the range of $2.45 to $2.65 per share, compared with its prior profit forecast of $2.15 to $2.35 per share.
BMO Capital Markets analyst Evan Seigerman said given the company's previous conservative forecast, the increase was somewhat expected. "Still, we are encouraged to see Pfizer executing where it matters," he wrote in a research note.
Pfizer also raised its full-year sales forecast for its antiviral treatment Paxlovid for high-risk COVID cases by $500 million to $3.5 billion.
Vyndaqel sales came in $200 million ahead of analyst estimates at $1.32 billion for the quarter, according to LSEG data.
Sales of bladder and urinary tract cancer treatment Padcev were $394 million for the quarter, beating estimates of $362 million.
Quarterly sales of the COVID vaccine Pfizer makes with German partner BioNTech 22UAy.DE were $195 million, while Paxlovid sales were $251 million. Analysts were expecting sales of $176 million for Comirnaty and $247.7 million for Paxlovid.
Pfizer was disappointed with its 2023 launch of RSV shot Abrysvo, but the company expressed optimism about the vaccine in the U.S. this year.
"We've significantly strengthened our contracting position," said Pfizer's Chief U.S. Commercial Officer Aamir Malik, noting that those decisions are set to take effect in August. Last year, rival GSK GSK.L won two-thirds of the RSV vaccine market, mostly due to its contracts with retail pharmacies.
Pfizer stock performance https://reut.rs/3WmEEiF
Second-quarter sales of Pfizer's drugs https://reut.rs/4cZVJ8Z
Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru and Michael Erman in New York; Editing by Anil D'Silva and Bill Berkrot
Gerelateerde activa
Laatste nieuws
Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.
Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.
Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.
